UY37635A - Anticuerpos anti phf-tau y sus usos - Google Patents

Anticuerpos anti phf-tau y sus usos

Info

Publication number
UY37635A
UY37635A UY0001037635A UY37635A UY37635A UY 37635 A UY37635 A UY 37635A UY 0001037635 A UY0001037635 A UY 0001037635A UY 37635 A UY37635 A UY 37635A UY 37635 A UY37635 A UY 37635A
Authority
UY
Uruguay
Prior art keywords
antibodies
phf
tau
bodies
tauopathies
Prior art date
Application number
UY0001037635A
Other languages
English (en)
Inventor
Marc Mercken
Thomas Malia
Marianne Borgers
Van Kolen Kristof
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY37635A publication Critical patent/UY37635A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos anti-PHF-tau monoclonales y fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y el uso de los anticuerpos para tratar o prevenir afecciones tales como tauopatías.
UY0001037635A 2017-03-16 2018-03-16 Anticuerpos anti phf-tau y sus usos UY37635A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
UY37635A true UY37635A (es) 2018-09-28

Family

ID=63521020

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037635A UY37635A (es) 2017-03-16 2018-03-16 Anticuerpos anti phf-tau y sus usos

Country Status (21)

Country Link
US (3) US10766953B2 (es)
EP (1) EP3596119A4 (es)
JP (2) JP7159185B2 (es)
KR (2) KR20230155025A (es)
CN (2) CN117209599A (es)
AR (1) AR111288A1 (es)
AU (1) AU2018234709A1 (es)
BR (3) BR122023021958A2 (es)
CA (1) CA3055598A1 (es)
CL (1) CL2019002566A1 (es)
EA (1) EA201992038A1 (es)
IL (2) IL310464A (es)
JO (1) JOP20180021A1 (es)
MA (1) MA47789A (es)
MX (1) MX2019010922A (es)
PH (1) PH12019501973A1 (es)
SG (1) SG11201907754RA (es)
TW (1) TWI771389B (es)
UY (1) UY37635A (es)
WO (1) WO2018170351A1 (es)
ZA (1) ZA202101318B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
UA124148C2 (uk) 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
TWI809562B (zh) 2017-10-16 2023-07-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
SG11202108414UA (en) 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
CN113950625A (zh) * 2019-05-31 2022-01-18 伊莱利利公司 靶向人tau的化合物和方法
EP4007773A1 (en) * 2019-08-06 2022-06-08 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
CN115697393A (zh) * 2020-04-08 2023-02-03 詹森生物科技公司 抗PHF-tau抗体及其用途
WO2022013286A1 (en) * 2020-07-14 2022-01-20 Janssen Pharmaceutica Nv Blood-based assay for detecting tauopathy or amyloidogenic disease
WO2022090169A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Method of safe administration of anti-tau antibody
EP4232155A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Methods of reducing tau in human subjects
CA3203800A1 (en) * 2021-02-19 2022-08-25 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
WO2022201123A1 (en) 2021-03-26 2022-09-29 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
EP0610330B1 (en) 1991-10-25 1997-06-18 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau
PT737208E (pt) * 1993-12-21 2006-12-29 Innogenetics Nv Anticorpos monoclonais específicos para phf-tau, hibridomas que os segregam, reconhecimento de antigénios por estes anticorpos e suas aplicações
CA2195672A1 (en) 1994-07-29 1996-02-15 Eugeen Vanmechelen Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
EP1590369B1 (en) 2003-01-24 2016-03-16 Applied Molecular Evolution, Inc. Human il-1 beta antagonists
AU2005214988A1 (en) 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP5406027B2 (ja) 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
WO2010054010A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
SG184452A1 (en) * 2010-04-09 2012-11-29 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
MX338421B (es) 2010-10-07 2016-04-15 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la proteina tau.
ES2686550T3 (es) * 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Anticuerpos anti-tau humanos
MY178142A (en) 2011-12-20 2020-10-05 Janssen Biotech Inc Anti-phf-tau antibodies and their uses

Also Published As

Publication number Publication date
TW201900682A (zh) 2019-01-01
IL268700A (en) 2019-10-31
US20180265575A1 (en) 2018-09-20
WO2018170351A8 (en) 2019-12-19
IL310464A (en) 2024-03-01
KR20190130133A (ko) 2019-11-21
AU2018234709A1 (en) 2019-08-29
CN110799531A (zh) 2020-02-14
CL2019002566A1 (es) 2019-12-27
BR112019019049A2 (pt) 2020-04-22
CN110799531B (zh) 2023-08-04
EP3596119A1 (en) 2020-01-22
JP2022191383A (ja) 2022-12-27
US10766953B2 (en) 2020-09-08
IL268700B1 (en) 2024-03-01
KR102597462B1 (ko) 2023-11-03
TWI771389B (zh) 2022-07-21
US11365244B2 (en) 2022-06-21
WO2018170351A1 (en) 2018-09-20
US20230047413A1 (en) 2023-02-16
CA3055598A1 (en) 2018-09-20
BR122023021947A2 (pt) 2024-02-20
EP3596119A4 (en) 2021-01-13
MA47789A (fr) 2020-01-22
JOP20180021A1 (ar) 2019-01-30
KR20230155025A (ko) 2023-11-09
JP7159185B2 (ja) 2022-10-24
US20210179696A1 (en) 2021-06-17
BR122023021958A2 (pt) 2024-02-20
PH12019501973A1 (en) 2020-06-29
EA201992038A1 (ru) 2020-02-06
ZA202101318B (en) 2023-03-29
CN117209599A (zh) 2023-12-12
MX2019010922A (es) 2019-11-08
SG11201907754RA (en) 2019-09-27
JP2020513804A (ja) 2020-05-21
AR111288A1 (es) 2019-06-26

Similar Documents

Publication Publication Date Title
UY37635A (es) Anticuerpos anti phf-tau y sus usos
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
DOP2019000165A (es) Anticuerpos anti-ox40 y sus usos
CL2020002314A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
ECSP18094829A (es) Anticuerpos anti-cd40 y sus usos
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
AR093394A1 (es) Anticuerpos especificos del factor de crecimiento b derivado de plaquetas (pdgf-b), composiciones y usos de estos
CR20180529A (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
CR20160593A (es) Anticuerpos antagonistas del interferon alfa y omega
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos
AR109825A1 (es) ANTICUERPOS DE INTERFERÓN b Y USOS DE LOS MISMOS
AR112758A1 (es) Anticuerpos agonistas que unen cd137 humano, y usos de los mismos